SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) | RFA CA 21 036

Opportunity Information: Apply for RFA CA 21 036

The SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44, Clinical Trial Optional) is a National Institutes of Health (NIH), National Cancer Institute (NCI) funding opportunity designed to help small businesses push promising, cancer-relevant innovations past the Phase II milestone and into true commercialization. It specifically targets projects that were already supported through an SBIR or STTR Phase II award from any federal agency, and it provides additional, later-stage resources to tackle the expensive and time-consuming work that typically sits between a successful Phase II and a product that is ready for real-world adoption. In other words, it is meant to close the "valley of death" between early federal R&D support and a market-ready technology, while keeping the focus on solutions that matter for cancer prevention, diagnosis, treatment, monitoring, or related areas of cancer care and research.

A core feature of this FOA is its emphasis on partnering and outside validation through independent, third-party capital. Applicants are expected to bring in, or credibly plan to bring in, substantial non-federal support during the Phase IIB project period from third-party investors and/or strategic partners. This could include private investors, venture capital, corporate partners, or other external sources that help finance commercialization-focused steps. The FOA makes the expectation very clear: the amount of independent third-party funding should be equal to or greater than the NCI funds requested across the Phase IIB Bridge Award period. That matching (or exceeding) investment is intended to signal market confidence, encourage investor alignment, and speed up development activities that are typically too capital-intensive for a small business to fund on its own.

To compete, applicants must submit a detailed Commercialization Plan, which serves as a central part of the application rather than a minor attachment. The plan should explain how the technology will move from its current Phase II state into a commercial product or service, what the remaining technical and regulatory milestones are, how the company will position the solution in the cancer marketplace, and how it will generate a sustainable business. Importantly, the plan must also spell out the third-party funding picture, including what has already been secured and what is anticipated, along with timing, amount, and the role those funds or partners will play during the award period. The overall message of the FOA is that NCI support is intended to bridge and accelerate progress, not replace the private or strategic investment usually required to launch a viable product.

The scientific and development scope is flexible in terms of stage, as long as the work is a logical next step beyond Phase II and is aimed at commercialization. Proposed activities may be preclinical, clinical, or a combination, depending on what the technology needs to reach the market. Clinical trials are explicitly allowed but not required, which gives applicants room to propose what is appropriate for their product type and maturity. For example, a diagnostics platform might need clinical validation studies, while a research tool or enabling technology might focus more on engineering scale-up, robustness testing, manufacturability, or regulatory planning. The "clinical trial optional" designation signals that the mechanism can support human studies when justified, but it does not force every project into that pathway.

Eligibility is centered on U.S. small business concerns, consistent with SBIR requirements, and the award mechanism is a grant under the R44 activity code. Foreign organizations are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, foreign components as defined under the NIH Grants Policy Statement may be allowed in limited circumstances, which typically means specific parts of the project might be performed abroad if strongly justified and compliant with NIH policy, while the applicant organization itself remains a U.S. small business.

From the posted opportunity details, the FOA is identified as RFA-CA-21-036, categorized as discretionary grant funding in the health area (CFDA numbers 93.394 and 93.395). The original closing date listed is 2021-08-06, and the opportunity was created on 2021-03-25. Overall, the program is best understood as an NCI commercialization accelerator for companies that already proved technical feasibility in Phase II and now need a structured, milestone-driven push, plus real investor/partner engagement, to reach a product launch or other meaningful commercial endpoint in the cancer space.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.395.
• This funding opportunity was created on 2021-03-25.
• Applicants must submit their applications by 2021-08-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA CA 21 036

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: